Research Paper Volume 13, Issue 8 pp 12207—12223

Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1

Silencing of SOX2 and CCAT1 decreases EGFR expression to suppress HepG2 cell proliferation, migration, and invasion. HepG2 cells were treated with sh-NC + oe-NC, sh-SOX2 + oe-NC, sh-CCAT1 + oe-NC, sh-SOX2 + oe-EGFR or sh-CCAT1 + oe-EGFR. (A) mRNA expression of EGFR in HepG2 cells detected by RT-qPCR normalized to β-actin. (B) Cell viability determined by MTT assay. (C, D) cell migration determined by Transwell assay (200 ×). (E, F) Cell invasion determined by Transwell assay (200 ×). * p vs. HepG2 treated with sh-NC + oe-NC. # p vs. HepG2 treated with sh-SOX2 + oe-NC. & p vs. HepG2 treated with sh-SOX2 + oe-NC. Data were expressed as mean ± standard deviation. Data from multiple groups were compared by one-way ANOVA and Tukey’s post hoc test. Data were compared between groups at different time points by repeated measures ANOVA and Bonferroni-corrected post hoc testing.

Figure 2. Silencing of SOX2 and CCAT1 decreases EGFR expression to suppress HepG2 cell proliferation, migration, and invasion. HepG2 cells were treated with sh-NC + oe-NC, sh-SOX2 + oe-NC, sh-CCAT1 + oe-NC, sh-SOX2 + oe-EGFR or sh-CCAT1 + oe-EGFR. (A) mRNA expression of EGFR in HepG2 cells detected by RT-qPCR normalized to β-actin. (B) Cell viability determined by MTT assay. (C, D) cell migration determined by Transwell assay (200 ×). (E, F) Cell invasion determined by Transwell assay (200 ×). * p < 0.05 vs. HepG2 treated with sh-NC + oe-NC. # p < 0.05 vs. HepG2 treated with sh-SOX2 + oe-NC. & p < 0.05 vs. HepG2 treated with sh-SOX2 + oe-NC. Data were expressed as mean ± standard deviation. Data from multiple groups were compared by one-way ANOVA and Tukey’s post hoc test. Data were compared between groups at different time points by repeated measures ANOVA and Bonferroni-corrected post hoc testing.